Dimensional Fund Advisors
MLYS icon

Dimensional Fund Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Dimensional Fund Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
463,387
+325,954
+237% +$8.94M ﹤0.01% 2217
2026
Q1 		$3.72M Sell
137,433
-203
-0.1% -$5.95K ﹤0.01% 2580
2025
Q4 		$4.99M Sell
137,636
-9,142
-6% -$367K ﹤0.01% 2527
2025
Q3 		$5.57M Sell
146,778
-40,606
-22% -$878K ﹤0.01% 2517
2025
Q2 		$2.54M Buy
187,384
+106,592
+132% +$1.54M ﹤0.01% 2704
2025
Q1 		$1.28M Buy
80,792
+64,380
+392% +$740K ﹤0.01% 2822
2024
Q4 		$202K Buy
+16,412
New +$215K ﹤0.01% 3166

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors's MLYS Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Mineralys Therapeutics (MLYS) stake by 237% in Q2 2026, buying an estimated $8.94M and bringing the position to 463,387 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Dimensional Fund Advisors first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Dimensional Fund Advisors held 463,387 shares of Mineralys Therapeutics worth $12.5M as of Q2 2026.
  • Dimensional Fund Advisors bought 325,954 Mineralys Therapeutics shares in Q2 2026, an estimated $8.94M.
  • Mineralys Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2217 holding.
  • Dimensional Fund Advisors first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.